Klingenstein Fields & Co. LLC decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 2.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,933 shares of the biopharmaceutical company’s stock after selling 1,783 shares during the quarter. Klingenstein Fields & Co. LLC’s holdings in Bristol-Myers Squibb were worth $4,840,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also made changes to their positions in the stock. Rockland Trust Co. lifted its position in Bristol-Myers Squibb by 3.4% during the third quarter. Rockland Trust Co. now owns 64,576 shares of the biopharmaceutical company’s stock valued at $4,116,000 after buying an additional 2,149 shares during the period. First Personal Financial Services lifted its position in Bristol-Myers Squibb by 11.4% during the third quarter. First Personal Financial Services now owns 8,792 shares of the biopharmaceutical company’s stock valued at $560,000 after buying an additional 898 shares during the period. Gamco Investors INC. ET AL lifted its position in Bristol-Myers Squibb by 0.4% during the third quarter. Gamco Investors INC. ET AL now owns 467,867 shares of the biopharmaceutical company’s stock valued at $29,822,000 after buying an additional 1,785 shares during the period. Blue Granite Capital LLC purchased a new position in Bristol-Myers Squibb during the third quarter valued at $583,000. Finally, Parnassus Investments CA purchased a new position in Bristol-Myers Squibb during the third quarter valued at $172,098,000. 69.66% of the stock is owned by institutional investors.
Several equities analysts have commented on the company. Barclays raised their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Jefferies Group lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Leerink Swann lifted their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Citigroup lifted their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $64.42.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $61.89 on Friday. Bristol-Myers Squibb Co has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a market capitalization of $101,300.00, a PE ratio of 24.37, a P/E/G ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the business posted $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.59%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.99%.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Shares Sold by Klingenstein Fields & Co. LLC” was posted by Equities Focus and is owned by of Equities Focus. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.equitiesfocus.com/2018/01/07/bristol-myers-squibb-co-bmy-shares-sold-by-klingenstein-fields-co-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.